Led by passionate experts

sensitivity, specificity, accuracy. For Better CAR-T Therapy

0
Satisfied Clients

Our clients range from leading multinational companies to small startups among 5 different countries.

0
Delivered Projects

With our products and services, our clients have successfully accomplished many projects in CAR T-Cell therapy field.

0
Trustworthy Suppliers

We have established robust supply chain.

WE’LL ENSURE YOU ALWAYS GET BEST RESULTS.

We provide accurate and convenient detection products and technical solutions for CAR T-Cell development, quality control and clinical monitoring.

Our product have the highest sensitivity for CAR T-Cell detection in the market.

More accurate!  more precise!  more sensitive!

Cytoart News

latest Blog Articles

accurate-detection-of-anti-cd19-car-t-cells

Accurate Detection of anti-CD19 CAR-T Cells

Application of R19M, An FMC63 scFv Idiotype Monoclonal Antibody Anti-CD19 CAR-T cell therapy With the development of cancer immunotherapy, Chimeric AntigenReceptor (CAR)-T cell, which combines

is-cd3ζ-alone-in-car-structure-good-enough?

Is CD3ζ alone in CAR structure good enough?

Two CD19-specific CARs approved by US FDA in 2017 have induced prominent responses in patients with refractory leukemia and lymphomas. However, Grade 3/4 CRS and

team-up:-car-t-meets-immune-checkpoint-inhibitor

Team up: CAR T meets Immune Checkpoint Inhibitor

Immune checkpoint inhibitor was undoubtedly a breakthrough in cancer therapy. Since FDA approved Pembrolizumab and Nivolumab for melanoma in 2014, PD-1/PD-L1 blockade has been proven